Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Free Report) and Takeda Pharmaceutical (NYSE:TAK – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations.
Analyst Ratings
This is a summary of current ratings and target prices for Zentalis Pharmaceuticals and Takeda Pharmaceutical, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Zentalis Pharmaceuticals | 1 | 1 | 7 | 1 | 2.80 |
| Takeda Pharmaceutical | 0 | 1 | 2 | 1 | 3.00 |
Zentalis Pharmaceuticals presently has a consensus price target of $8.29, indicating a potential upside of 387.39%. Given Zentalis Pharmaceuticals’ higher probable upside, research analysts plainly believe Zentalis Pharmaceuticals is more favorable than Takeda Pharmaceutical.
Valuation & Earnings
This table compares Zentalis Pharmaceuticals and Takeda Pharmaceutical”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Zentalis Pharmaceuticals | $67.43 million | 1.81 | -$137.06 million | ($1.92) | -0.89 |
| Takeda Pharmaceutical | $4,693.24 billion | 0.01 | -$1.01 billion | $0.76 | 28.20 |
Zentalis Pharmaceuticals has higher earnings, but lower revenue than Takeda Pharmaceutical. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Zentalis Pharmaceuticals has a beta of 1.91, indicating that its stock price is 91% more volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of -0.02, indicating that its stock price is 102% less volatile than the S&P 500.
Institutional & Insider Ownership
9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 3.8% of Zentalis Pharmaceuticals shares are owned by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Zentalis Pharmaceuticals and Takeda Pharmaceutical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Zentalis Pharmaceuticals | N/A | -75.82% | -55.15% |
| Takeda Pharmaceutical | 8.26% | 11.51% | 5.59% |
Summary
Takeda Pharmaceutical beats Zentalis Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
About Zentalis Pharmaceuticals
Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for cancer. Its research centers on therapies that target biological processes involved in tumor growth. The company’s lead drug candidate, azenosertib (formerly known as ZN-c3), is an investigational inhibitor of WEE1, a protein involved in cell-cycle regulation. It has been studied in clinical trials for ovarian cancer and other solid tumors. Zentalis has also advanced other oncology drug candidates, including compounds targeting cancer-related proteins.
About Takeda Pharmaceutical
Takeda Pharmaceutical Company is a Japan-based global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Founded in Osaka in 1781 as a medicine wholesaler, it has grown into an international pharmaceutical business headquartered in Tokyo. The company focuses on gastroenterology and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Its portfolio includes treatments for conditions such as inflammatory bowel disease and hereditary angioedema, along with medicines and vaccines across its other therapeutic areas.
Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
